Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options.

@article{Kim2015HematopoieticSC,
  title={Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options.},
  author={Sara Kim and Monank Patel and Kendra Yum and Alla Keyzner},
  journal={Transfusion},
  year={2015},
  volume={55 2},
  pages={452-8}
}
BACKGROUND Transplant-associated thrombotic microangiopathy (TA-TMA) is a multifactorial disorder, which occurs as a result of treatment-related endothelial injury and underlying disease process after hematopoietic stem cell transplantation (HSCT). The reported incidence of TA-TMA after HSCT is 0% to 74% and has shown to be associated with mortality rate of up to 100%. TA-TMA is often diagnosed late in the disease progression, and therapeutic plasma exchange (TPE) has not been shown to produce… CONTINUE READING